Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Ras Gene02:38

The Ras Gene

7.0K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
7.0K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

5.2K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
5.2K
GTPases and their Regulation02:14

GTPases and their Regulation

9.7K
Guanine nucleotide-binding proteins (G-proteins), also known as GTPases, are a superfamily of proteins that regulate many cellular processes, such as cell signaling, vesicular transport, and the regulation of cell shape and motility. Mutation or dysfunction of these proteins can lead to disease. There are around 40,000 known G-proteins that can broadly be classified into two groups ‒  small G-proteins consisting of a single domain and large multi-domain G-proteins.
Large G-proteins,...
9.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Selective Inhibition of KRASG13C Reveals an Increased Dependence on Wild-Type RAS Isoforms in Codon 13 RAS-Mutant Cancers.

Cancer discovery·2026
Same author

Targeting KRAS codon 13 mutations using direct combination approaches in non-small cell lung cancer.

Cancer discovery·2026
Same author

Langevin and Fokker-Planck analyses for diffusion-mediated passing of circular and discorectangular species in two-dimensional channels.

Physical review. E·2026
Same author

Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition.

Cell reports·2026
Same author

Disrupted molecular glue complex drives RAS inhibitor resistance.

Cell·2026
Same author

Characterization and therapeutic suppression of KEAP1-NRF2-driven resistance to KRAS inhibitors in pancreatic and lung cancer.

bioRxiv : the preprint server for biology·2026
Same journal

DNA, Peptide Vaccines Advance Against GBM.

Cancer discovery·2026
Same journal

AKR1C1 Promotes ADC Resistance by Altering Uptake and Export.

Cancer discovery·2026
Same journal

Acquisition of Centromeric Features Supports Telomere Integrity.

Cancer discovery·2026
Same journal

Germline CDK12 variants in aggressive prostate cancer.

Cancer discovery·2026
Same journal

Type II JAK2 Inhibitor Gets Off to a Strong Start.

Cancer discovery·2026
Same journal

Pancreatic Cancer: Translating Tumor Biology into Actionability.

Cancer discovery·2026
See all related articles

Related Experiment Video

Updated: Jan 16, 2026

RhoC GTPase Activation Assay
09:58

RhoC GTPase Activation Assay

Published on: August 22, 2010

13.0K

Correction: Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers

Jingjing Jiang, Lingyan Jiang, Benjamin J Maldonato

    Cancer Discovery
    |October 6, 2025
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
    08:12

    Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

    Published on: October 5, 2020

    3.3K
    Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
    07:42

    Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

    Published on: September 19, 2018

    8.3K

    Related Experiment Videos

    Last Updated: Jan 16, 2026

    RhoC GTPase Activation Assay
    09:58

    RhoC GTPase Activation Assay

    Published on: August 22, 2010

    13.0K
    Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
    08:12

    Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

    Published on: October 5, 2020

    3.3K
    Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
    07:42

    Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

    Published on: September 19, 2018

    8.3K